Drug Trial Radar · NCT07452224
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jun 29, 2026
Primary completion
Jun 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- iLeukon Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, phase II study to evaluate the safety, tolerability, clinical activity, and pharmacokinetics of ILKN421H in combination with pembrolizumab in participants with locally advanced or metastatic NSCLC. The study consists of 4 cohorts in participants with locally advanced or metastatic NSCLC ( squamous \[sq\] or non-squamous \[non-sq\]) without functional genomic alterations including EGFR, ALK and Ros-1, who failed systemic PD-1/L1 inhibitor treatment either alone or in combination with standard chemotherapy (post-IO) (Cohort 1 and 2), or without any prior systemic anti-cancer therapy (1L) with PDL-1 TPS ≥1% (Cohort 3 and 4). Participants will be dosed either with 1.6 mg of ILKN421H (Cohort 1 and Cohort 3) or 2.4 mg of ILKN421H (Cohort 2 and Cohort 4) in combination with 200 mg pembrolizumab. Both treatments will be administered through intravenous (i.v.) infusion every 3 weeks (Q3W) on Day 1 of each cycle with 21-day as one cycle, while ILKN421H will be dosed 4 hours after pembrolizumab. All 4 cohorts will have 3 study periods: * Screening Period: ≤ 28 days prior to first dose of study treatment; * Treatment period: 21-day cycles until unacceptable toxicity, lost to follow-up, disease progression, withdrawal of consent, death, or the sponsor closes the study, whichever occurs first; * Follow-up Period: 30-day safety follow-up and a Long-Term follow-up every 6-month for survival information.
Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
ILKN421HDrug
Participants will receive ILKN421H in combination with pembrolizumab once every 3 weeks (Q3W). ILKN421H will be administered via i.v. infusion, starting at a rate of 75 mL/h for the first 20 minutes. If no infusion-related reactions are observed, the infusion rate can be increased to 150 mL/h for the remainder of the infusion.
PembrolizumabDrug
Pembrolizumab will be administered intravenously first. After the infusion ends, at least 4 hours must pass before the intravenous infusion of ILKN421H can begin. Each infusion will last for 1 hour, and the infusion rate will follow the same guidelines
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.Time frame: Up to 3 years.
- To assess the ORR(Objective response rate) in the treatment of Locally Advanced or Metastatic Non-Small Cell Lung CancerTime frame: up to 3 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Valkyrie Clinical Trials, Inc
Los Angeles, California · Recruiting
Start Ccbd, Llc
Fort Worth, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.